Man Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Man Group’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.81M	Sell	765,786 -433,777	-36%	-$1.44M	﹤0.01%	1402
2026 Q1	$3.68M	Buy	1,199,563 +1,171,603	+4,190%	+$4.53M	0.01%	1309
2025 Q4	$114K	Buy	+27,960	New	+$138K	﹤0.01%	2186
2025 Q1	–	Sell	-70,802	Closed	-$479K	–	2337
2024 Q4	$479K	Buy	+70,802	New	+$476K	﹤0.01%	1684
2024 Q3	–	Sell	-27,971	Closed	-$210K	–	2173
2024 Q2	$210K	Buy	+27,971	New	+$244K	﹤0.01%	1880
2023 Q1	–	Hold	0	–	–	–	1833
2022 Q4	–	Sell	-10,671	Closed	-$114K	–	2180
2022 Q3	$114K	Buy	+10,671	New	+$108K	﹤0.01%	1841

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Man Group's RXRX Position: Q2 2026 in Review

Man Group reduced its Recursion Pharmaceuticals (RXRX) stake by 36% in Q2 2026, selling an estimated $1.44M and leaving 765,786 shares worth $2.81M. The position accounts for ﹤0.01% of the portfolio, ranked #1402.

Man Group first reported a position in RXRX in Q3 2022 and has held it in 6 quarters since. The position peaked at $3.68M in Q1 2026. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Man Group held 765,786 shares of Recursion Pharmaceuticals worth $2.81M as of Q2 2026.
Man Group sold 433,777 Recursion Pharmaceuticals shares in Q2 2026, an estimated $1.44M.
Recursion Pharmaceuticals made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1402 holding.
Man Group first reported a position in Recursion Pharmaceuticals in Q3 2022 and has held it in 6 quarters since.
Man Group's Recursion Pharmaceuticals position peaked at $3.68M in Q1 2026.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.